FDA Seeks Ways to Boost Antibacterial Drug Pipeline

Published September 26, 2012

FDA seeks ways to boost antibacterial drug pipeline

Filed under: drug treatment news 2012

And Cubist Pharmaceuticals ($ CBST) expects $ 1 billion in sales by 2017 from its antibiotic, targeted at difficult-to-treat skin and bloodstream infections. Enanta Pharmaceuticals, a 2012 Fierce 15 company, is developing drugs in this field. Still with …
Read more on FierceBiotech

Genetic Link To PTSD Could Lead To Vet Drug Treatment

Filed under: drug treatment news 2012

A recent study that discovered a genetic link to Post Traumatic Stress Disorder (PTSD) could ultimately lead to breakthroughs in treatment or prevention, but advances are at least a decade away because additional research is needed, according to the …
Read more on West Hartford News

GENFIT : HALF-YEAR RESULTS FOR 2012

Filed under: drug treatment news 2012

… a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its financial results for the first half of 2012.
Read more on Reuters

Valeant buys Visudyne drug from QLT; QLT stock jumps

Filed under: drug treatment news 2012

TORONTO | Mon Sep 24, 2012 10:09am EDT. TORONTO (Reuters) – Valeant Pharmaceuticals International Inc said on Monday it has acquired Visudyne, a drug used to treat age-related blindness, from Canadian biotech firm QLT Inc for $ 112.5 million.
Read more on Reuters